Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
Richard Scolyer, 59, renowned Australian cancer specialist and co-medical director at Melanoma Institute Australia, dies after pioneering an experimental brain tumour treatment, leaving a legacy in melanoma care through his work with immunotherapy.
Prof Richard Scolyer, a celebrated cancer researcher and 2024 Australian of the Year, has died at 59 after a public battle with inoperable brain cancer, leaving a legacy of inspiration and groundbreaking medical contributions.
An experimental drug, GRWD5769, has shown promise in early trials by shrinking tumors by at least 30% in six common cancer types. The drug works by preventing cancer cells from hiding from the immune system, making immunotherapy treatments more effective.
A personalized mRNA vaccine combined with Keytruda significantly reduced the risk of melanoma recurrence and death in a clinical trial. The therapy, which trains T cells to target unique tumor neoantigens, showed 68.8% of patients remained cancer-free after five years, compared to 49.1% with Keytruda alone.
Oncologists in Tyumen, Russia, have achieved the country's first successful treatment of anaplastic thyroid cancer using immunotherapy. After two years of treatment, the patient's tumor has completely disappeared, and she can breathe and eat independently.
NHS England introduces a new injectable form of Keytruda (pembrolizumab) that cuts treatment time from over an hour to just 1-2 minutes. Around 14,000 cancer patients in England who start Keytruda each year will benefit from the faster administration, with the 86-year-old pilot patient describing the difference as transformative for her quality of life.
A new injectable form of Keytruda (pembrolizumab) is being rolled out across the NHS, reducing treatment time from over an hour to just 1-2 minutes. Around 14,000 English cancer patients starting Keytruda annually will benefit, with the jab now available for 14 cancer types including lung, cervical and breast.
NHS England introduces a new injectable form of Keytruda (pembrolizumab) that cuts treatment time from over an hour to just 1-2 minutes. About 14,000 cancer patients in England who start Keytruda each year will benefit from the faster administration, which treats 14 cancer types including lung, head and neck, cervical and breast cancers.
ESPN Hall of Fame broadcaster Dick Vitale announced he has been diagnosed with melanoma in his lung and liver cavity and will soon begin immunotherapy. This marks his fifth battle with cancer.
